Jubilant Life Sciences said it received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its solid dosage facility at Salisbury, Maryland, USA.
Jubilant Pharma, a material wholly owned subsidiary of Jubilant Life Sciences, has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the United States Food & Drug Administration (USFDA) for its solid dosage facility at Salisbury, Maryland, USA in respect of the inspection conducted by the US-based drug regulator from 24 February 2020 to 28 February 2020.
With the receipt of the EIR, the inspection stands successfully closed. The disclosure was released after trading hours yesterday, 31 March 2020.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and other businesses including drug discovery solutions.
Shares of Jubilant Life Sciences was locked in 10% upper-circuit at Rs 273.70 on BSE. The stock traded in the range of Rs 252.05 to Rs 273.70 so far.
Powered by Capital Market - Live News